Single-arm salvage therapy with pegylated interferon alfa-2a for patients with high-risk polycythemia vera or high-risk essential thrombocythemia who are either hydroxyurea-resistant or intolerant: Final results of the Myeloproliferative Disorders-Research Consortium (MPD-RC) Protocol 111 global phase II trial Meeting Abstract


Authors: Yacoub, A.; Mascarenhas, J.; Kosiorek, H. E.; Prchal, J. T.; Berenzon, D.; Baer, M. R.; Ritchie, E. K.; Silver, R. T.; Kessler, C. M.; Winton, E. F.; Finazzi, M. C.; Rambaldi, A.; Vannucchi, A. M.; Leibowitz, D. S.; Rondelli, D.; Arcasoy, M. O.; Catchatourian, R.; Vadakara, J.; Rosti, V.; Hexner, E.; Kremyanskaya, M.; Orellana, A.; Sandy, L.; Tripodi, J.; Najfeld, V.; Salama, M. E.; Weinberg, R. S.; Rampal, R. K.; Mesa, R. A.; Goldberg, J. D.; Dueck, A. C.; Hoffman, R.
Abstract Title: Single-arm salvage therapy with pegylated interferon alfa-2a for patients with high-risk polycythemia vera or high-risk essential thrombocythemia who are either hydroxyurea-resistant or intolerant: Final results of the Myeloproliferative Disorders-Research Consortium (MPD-RC) Protocol 111 global phase II trial
Meeting Title: 59th Annual Meeting of the American Society of Hematology (ASH)
Journal Title: Blood
Volume: 130
Issue: Suppl. 1
Meeting Dates: 2017 Dec 9-12
Meeting Location: Atlanta, GA
ISSN: 0006-4971
Publisher: American Society of Hematology  
Date Published: 2017-12-07
Language: English
ACCESSION: WOS:000432419400376
PROVIDER: wos
Notes: Meeting Abstract: 321 -- Source: Wos
MSK Authors
  1. Raajit Kumar Rampal
    128 Rampal
Related MSK Work